News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
812,893 Results
Type
Article (75387)
Company Profile (643)
Press Release (736863)
Section
Business (227741)
Career Advice (3771)
Deals (39167)
Drug Delivery (127)
Drug Development (89165)
Employer Resources (195)
FDA (17786)
Job Trends (17086)
News (387683)
Policy (38720)
Tag
Academia (2979)
Alliances (56011)
Alzheimer's disease (1426)
Approvals (17737)
Artificial intelligence (236)
Bankruptcy (397)
Best Places to Work (12632)
Biotechnology (440)
Breast cancer (243)
Cancer (1845)
Cardiovascular disease (149)
Career advice (3208)
CAR-T (140)
Cell therapy (403)
Clinical research (71329)
Collaboration (722)
Compensation (383)
COVID-19 (2837)
C-suite (175)
Data (1674)
Diabetes (234)
Diagnostics (6825)
Earnings (92866)
Employer resources (167)
Events (127332)
Executive appointments (602)
FDA (18739)
Funding (648)
Gene therapy (283)
GLP-1 (774)
Government (5058)
Healthcare (20818)
Infectious disease (2961)
Inflammatory bowel disease (135)
Interviews (739)
IPO (17661)
Job creations (4969)
Job search strategy (2625)
Layoffs (520)
Legal (9891)
Lung cancer (276)
Manufacturing (267)
Medical device (14498)
Medtech (14503)
Mergers & acquisitions (21873)
Metabolic disorders (634)
Neuroscience (1884)
NextGen: Class of 2025 (7631)
Non-profit (5076)
Northern California (2149)
Obesity (355)
Opinion (261)
Patents (174)
People (63637)
Phase I (22019)
Phase II (31116)
Phase III (23448)
Pipeline (743)
Postmarket research (3280)
Preclinical (9704)
Radiopharmaceuticals (263)
Rare diseases (363)
Real estate (7148)
Regulatory (25680)
Research institute (2645)
Resumes & cover letters (589)
Southern California (1853)
Startups (4183)
United States (19768)
Vaccines (722)
Weight loss (269)
Date
Today (132)
Last 7 days (658)
Last 30 days (2902)
Last 365 days (37176)
2025 (4803)
2024 (37915)
2023 (42567)
2022 (53927)
2021 (58722)
2020 (57665)
2019 (51316)
2018 (39098)
2017 (36857)
2016 (37795)
2015 (43821)
2014 (38556)
2013 (34692)
2012 (36543)
2011 (36597)
2010 (36130)
Location
Africa (1196)
Arizona (227)
Asia (48156)
Australia (8290)
California (5020)
Canada (1752)
China (420)
Colorado (230)
Connecticut (253)
Europe (109438)
Florida (712)
Georgia (177)
Illinois (528)
Indiana (281)
Maryland (807)
Massachusetts (3912)
Michigan (222)
Minnesota (361)
New Jersey (1419)
New York (1419)
North Carolina (979)
Northern California (2149)
Ohio (186)
Pennsylvania (1132)
South America (1568)
Southern California (1853)
Texas (743)
Utah (150)
Washington State (509)
812,893 Results for "merck and co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
Cancer
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, according to analysts at Truist Securities.
February 18, 2025
·
2 min read
·
Tristan Manalac
Legal
RFK Jr.-Linked Lawsuit Against Merck Suspended After Confirmation:
Reuters
Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, alleging injury linked to its HPV shot Gardasil.
February 19, 2025
·
2 min read
·
Tristan Manalac
Cancer
Merck and Epitopea Join Forces to Identify Unknown Tumor Antigens
The agreement, in which Merck will pay the biotech an undisclosed initial sum to license drugs targeting a solid tumor, could net Epitopea up to $300 million down the line.
February 19, 2025
·
1 min read
·
Dan Samorodnitsky
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
February 4, 2025
·
4 min read
·
Annalee Armstrong
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
·
2 min read
·
Kate Goodwin
Pipeline
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year.
January 15, 2025
·
4 min read
·
Tristan Manalac
Manufacturing
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
January 6, 2025
·
1 min read
·
Annalee Armstrong
Collaboration
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal
Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.
November 14, 2024
·
2 min read
·
Tristan Manalac
Lymphoma
Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment
Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.
December 9, 2024
·
2 min read
·
Tristan Manalac
1 of 81,290
Next
